MOXIFLOXACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H24FN3O4
Molecular Weight	401.4314
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(OC)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N

InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361

Moxifloxacin is a synthetic antibacterial agent developed by Bayer AG (initially called BAY 12-8039) for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Moxifloxacin is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avalon for oral treatment. In most countries, the drug is also available in the parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV subunit A 7 Target ID: CHEMBL4088 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16337789	Inhibitor 8297		800.0 nM [IC50]
DNA gyrase subunit A 7 Target ID: CHEMBL4165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20516287	Inhibitor 8297		9200.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Community acquired pneumonia 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf	Curative	Approved 8429	AVELOX Approved Use INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 1999
Plague 14 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf	Curative	Approved 8429	AVELOX Approved Use INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 1999
Acute bacterial sinusitis 26 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf	Curative	Approved 8429	AVELOX Approved Use INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 1999

C_max

Value	Dose	Analyte	Population
3.1 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.9 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.5 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
443.07 ng/ml Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01296191	1 drop 4 times / day multiple, ocular dose: 1 drop route of administration: ocular experiment type: multiple co-administered:	MOXIFLOXACIN aqueous humor	Homo sapiens population: unhealthy age: sex: food status:

AUC

Value	Dose	Analyte	Population
36.1 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
38 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
39.3 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
48 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
13.55 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
14.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
60% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
60% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered:		MOXIFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 1 times / day multiple, oral Higher than recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11352436 Page: p.5	healthy, 30±7 n = 7 Health Status: healthy Age Group: 30±7 Sex: M Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/11352436 Page: p.5	Sources: https://pubmed.ncbi.nlm.nih.gov/11352436 Page: p.5
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9687407 Page: p.2062	healthy, 33.6 n = 8 Health Status: healthy Age Group: 33.6 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/9687407 Page: p.2062	Sources: https://pubmed.ncbi.nlm.nih.gov/9687407 Page: p.2062
400 mg 1 times / day multiple, intravenous Recommended Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (>0.3) Diarrhea (>0.3) Dizziness (>0.3) Vomiting (>0.3) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23343427 Page: p.7	unhealthy, 57.8 n = 5 Health Status: unhealthy Condition: Chronic bronchitis Age Group: 57.8 Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/23343427 Page: p.7	Sources: https://pubmed.ncbi.nlm.nih.gov/23343427 Page: p.7
400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	Disc. AE: Erythema, QT interval prolonged... AEs leading to discontinuation/dose reduction: Erythema (0.37%) QT interval prolonged (1%) Angioedema (serious, 0.37%) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	Disc. AE: Tendinitis, Tendon rupture... AEs leading to discontinuation/dose reduction: Tendinitis Tendon rupture Peripheral neuropathy Central nervous system disorder NOS Myasthenia gravis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Rash	Disc. AE	400 mg 1 times / day multiple, intravenous Recommended Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Diarrhea	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Dizziness	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Nausea	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Vomiting	>0.3 Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9	unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.8.9
Erythema	0.37% Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
QT interval prolonged	1% Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
Angioedema	serious, 0.37% Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863	unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: https://pubmed.ncbi.nlm.nih.gov/30722059 Page: p.1863
Central nervous system disorder NOS	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Myasthenia gravis	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Peripheral neuropathy	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Tendinitis	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1
Tendon rupture	Disc. AE	400 mg 1 times / day multiple, oral\|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral\|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63611	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63611
MolPort	MolPort-006-167-494	https://www.molport.com/shop/molecule-link/MolPort-006-167-494
ZINC	ZINC000003826253	http://zinc15.docking.org/substances/ZINC000003826253
eMolecules	6843461	https://www.emolecules.com/cgi-bin/more?vid=6843461

PubMed

Title	Date	PubMed
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.	2001	11713894
Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains.	2001	11688532
Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint.	2001	11549786
Comparison of side effects of levofloxacin versus other fluoroquinolones.	2001	11549784
Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.	2001	11352445
Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.	2001	11352443
Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.	2001	11352442
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	2001 Apr	11404068
Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana.	2001 Aug	11576793
Treatment of Staphylococcus aureus endocarditis using moxifloxacin.	2001 Aug	11554565
In vitro activity of fosfomycin in combination with various antistaphylococcal substances.	2001 Aug	11481290
The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues.	2001 Aug	11481288
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.	2001 Aug 15	11462189
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.	2001 Feb	11336589
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.	2001 Jul	11561805
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	2001 Jul	11463526
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.	2001 Jul	11453311
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.	2001 Jul	11446520
Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.	2001 Jul	11418530
[Hypertensive crisis and transitory left brunch block with QT interval prolongation associated to moxifloxacin].	2001 Jul 7	11481090
A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.	2001 Jul-Aug	11675905
Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.	2001 Jun	11452678
Microbial drug resistance and the roles of the new antibiotics.	2001 Jun	11405611
Conventional dogma applied to quinolones? Time for a change.	2001 Jun	11389126
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	2001 Jun	11389122
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.	2001 Mar	11337189
Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.	2001 Mar-Apr	11393351
Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients.	2001 Mar-Apr	11393350
Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.	2001 Mar-Apr	11393349
Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia.	2001 May	11422407
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.	2001 May	11337224
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	2001 May-Jun	11448561
Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.	2001 Nov	11679555
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.	2001 Nov	11679549
[Diagnosis and therapy of abscess forming pneumonia].	2001 Oct	11695090
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.	2001 Oct	11691572
Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.	2001 Oct	11691571
Pharmacokinetics and pharmacodynamics of fluoroquinolones.	2001 Oct	11642690
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.	2001 Oct	11581236
Moxifloxacin does increase the corrected QT interval.	2001 Oct 15	11565091
In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.	2001 Sep	11605808
The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.	2001 Sep	11594251
Is more than one quinolone needed in clinical practice?	2001 Sep	11573860
Future of the quinolones.	2001 Sep	11562902
Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.	2001 Sep	11533016
Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure.	2001 Sep	11533002
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.	2001 Sep	11533001
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.	2001 Sep 15	11517444
In vitro susceptibility study of BMS-284756 against Legionella species.	2001 Sep-Oct	11687318
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.	2001 Sep-Oct	11561138

Patents

Sample Use Guides

In Vivo Use Guide

The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection (5--21 days).

Route of Administration: Oral

In Vitro Use Guide

Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. Moxifloxacin was active against all tested staphylococci with MICs of 0.063–2 mg/L.

Name

Type

Language

MOXIFLOXACIN

Official Name

English

moxifloxacin [INN]

Common Name

English

AVELOX IV

Brand Name

English

1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-((4AS,7AS)-OCTAHYDRO-6H-PYRROLO(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID

Common Name

English

Moxifloxacin [WHO-DD]

Common Name

English

MOXIFLOXACIN [VANDF]

Common Name

English

ZIMOXIN

Brand Name

English

MOXIFLOXACIN [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

S01AX22